Bone-marrow and splenocyte cells harvested from mice treated with CML-07–119 displayed significantly higher concentration of unprenylated RAP1A as compared to the controls, demonstrating the expected biochemical outcome of in vivo GGPPS inhibition. Here, GGPS1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.